La Jolla Pharmac. - mit Potential? - 500 Beiträge pro Seite

[GrazerChris]

Wenn der Durchbruch von LJP 394 gelingt, gibt`s kein Halten mehr!

Hier einige News:


La Jolla Pharmaceutical Scientist presentS LUPUS BLOOD test results at
KEYSTONE 2000 IMMUNOLOGY CONFERENCE


San Diego, April 4, 2000 - La Jolla Pharmaceutical Company`s (Nasdaq: LJPC)
Executive Vice President of Research, Dr. Matt Linnik, today presented the
methods and results of a blood test used in analyzing data from its recent
lupus clinical trials at the Keystone Symposia 2000 in Steamboat Springs,
Colorado, titled: "The Mechanism of Immunologic Tolerance and its
Breakdown." This blood test measures the strength of the binding between a
patient`s antibodies to double-stranded DNA and the Company`s lupus drug
candidate, LJP 394. In November the Company reported that more than 80% of
patients in its Phase II/III lupus clinical trial tested positive by this
blood assay.

The presentation was based on research conducted between 1998 and 1999,
published in 1999 in the Archives of Biochemistry and Biophysics (Volume
372, pages 62-68) which describes how the test measured the affinity of LJP
394 for lupus patient`s antibodies to double-stranded DNA using a technique
called surface plasmon resonance. The approach enables real time binding
measurements without radioactive labeling of biomolecules such as
antibodies. In these studies, LJP scientists showed that the approach can
measure the average binding affinity of polyclonal antibodies in a
repeatable manner and validated a mathematical model of the molecular
interaction.

Lupus is a life-threatening autoimmune disease afflicting more than one
million people in the United States and Europe. Half of the patients have
renal disease and 90% are female. LJP 394 is designed to reduce the level
of antibodies to double-stranded DNA that are believed to promote kidney
disease, a primary cause of morbidity and mortality in lupus patients. When
the drug binds to
B-cells that produce antibodies to double-stranded DNA, this action delivers
a specific and potent signal that arrests their production. La Jolla
Pharmaceutical is continuing to analyze data from the trial.

San Diego-based La Jolla Pharmaceutical Company is focused on the research
and development of therapeutic compounds to treat antibody-mediated
autoimmune
diseases. The Company develops disease-specific therapeutics using its
proprietary Tolerance Technology® for major diseases and conditions caused
by antibodies. By treating the underlying cause of disease, the Company
believes that use of its Tolerance Technology will lead to products with
improved therapeutic benefit and fewer side effects than currently available
therapies.

The Company is developing targeted therapeutics for major diseases and
conditions caused by antibodies such as lupus, antibody-mediated thrombosis
(a clotting disorder associated with stroke, myocardial infarction,
deep-vein thrombosis and recurrent fetal loss) and organ rejection in
xenotransplantation. The Company`s common stock and warrants trade on The
Nasdaq Stock Market under the symbols LJPC and LJPCW, respectively. For
more information about the Company, visit our website: www.ljpc.com.

Statements regarding the analysis of results from preclinical and clinical
studies, as well as La Jolla Pharmaceutical`s drug candidates and drug
development plans, are forward-looking statements involving risks and
uncertainties, and a number of factors, both foreseen and unforeseen, could
cause actual results to differ materially from those anticipated. The
Company`s analysis of clinical results is ongoing, and future analyses may
not necessarily support conclusions to date. Clinical results are derived
from a trial that was terminated prior to completion, and certain data may
be incomplete. The Company`s blood test for LJP 394 is experimental and has
not been validated by independent laboratories. Tolerance, or the specific
inactivation of pathogenic B cells, is a new technology that has not been
proven. Future clinical trials of LJP 394 may have negative or inconclusive
results. Further, delays in continued testing of LJP 394 and/or termination
of development by the Company would result in delays or lack of government
approval to market the compound. The development of LJP 394 involves many
risks and uncertainties, including, without limitation, whether LJP 394 can
provide a meaningful clinical benefit, and any positive results observed to
date may not be indicative of future results. La Jolla Pharmaceutical`s
other drug candidates, none of which has progressed to clinical trials,
involve comparable risks. Interested parties are urged to review the risks
detailed from time to time in La Jolla Pharmaceutical Company`s Securities
and Exchange Commission (SEC) filings, including the report on Form 10-K for
the year ended December 31, 1999.

[Capt.Janeway]

Die Meldung ist super,

doch die Beachtung für diese Aktie ist gleich null!!!

Mehr Werbung auf diesem oder anderen Boards wäre günstiger
(z.B. Ariva !!)

[epicuraul]

ja genau!
macht mal werbung, ich bin auch noch drin!

[GrazerChris]

Hier die letzten News!!


DATE: May 2, 2000

CONTACT: Andrew Wiseman, Ph.D.

RELEASE DATE: Immediate


LA JOLLA PHARMACEUTICAL MEETS WITH FDA ON LUPUS DRUG CANDIDATE

SAN DIEGO, May 2, 2000 - La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that after a positive meeting with the Food and Drug Administration last week, it plans to conduct a Phase III trial of its lupus drug candidate, LJP 394. The Company expects to begin the trial in the second half of this year.

The Company previously announced encouraging results from a Phase II/III trial of
LJP 394 in more than 200 lupus patients. Results from the Phase II/III trial indicate that there was a statistically significant reduction in the time to renal flare and in the incidence of treatments with high-dose corticosteroids or cyclophosphamide in lupus patients with high affinity antibodies to LJP 394. Renal flares and treatments with high-dose corticosteroids or cyclophosphamide are the leading causes of morbidity and mortality in lupus patients. The Company is continuing to analyze data from the trial.

La Jolla Pharmaceutical is focused on the research and development of therapeutic compounds to treat antibody-mediated diseases such as lupus, antibody-mediated thrombosis-a clotting disorder associated with stroke, myocardial infarction, deep-vein thrombosis and recurrent fetal loss-and organ rejection in xenotransplantation. The Company develops disease-specific therapeutics using its proprietary Tolerance Technology® for major diseases and conditions caused by antibodies. By treating the underlying cause of disease, the Company believes that Tolerance Technology will lead to products with improved therapeutic benefit and fewer side effects than currently available treatments. The Company`s common stock and warrants trade on The Nasdaq Stock Market under the symbols LJPC and LJPCW, respectively. For more information about the Company, visit our website: www.ljpc.com.

Statements regarding the analysis of results from preclinical and clinical studies, as well as La Jolla Pharmaceutical`s drug candidates and drug development plans, are forward-looking statements involving risks and uncertainties, and a number of factors, both foreseen and unforeseen, could cause actual results to differ materially from those anticipated. The Company`s analysis of clinical results is ongoing, and future analyses may not necessarily support conclusions to date. The Company`s blood test to measure binding affinity for LJP 394 is experimental and has not been validated by independent laboratories. Tolerance, or the specific inactivation of pathogenic B cells, is a new technology that has not been proven. Future clinical trials of LJP 394 may have negative or inconclusive results. Further, delays in continued testing of LJP 394 and/or termination of development by the Company would result in delays or lack of government approval to market the compound. The development of LJP 394 involves many risks and uncertainties, including, without limitation, whether LJP 394 can provide a meaningful clinical benefit, and any positive results observed to date may not be indicative of future results. La Jolla Pharmaceutical`s other drug candidates, including its Toleragen candidates for antibody-mediated thrombosis and for xenotransplantation, none of which has progressed to clinical trials, involve comparable risks. Interested parties are urged to review the risks detailed from time to time in La Jolla Pharmaceutical Company`s Securities and Exchange Commission (SEC) filings, including the report on Form 10-K for the year ended December 31, 1999